Overview
- The companies announced the exclusive collaboration on Monday, June 8, 2026, under which Nurix will receive $700 million up front and may earn up to $2.3 billion in milestones.
- Roche will pay 60% of development costs while Nurix pays 40%, the firms will co‑commercialise in the United States with profits and losses split equally, and Roche will sell the drug outside the U.S. with Nurix receiving royalties.
- Bexobrutideg (NX‑5948) is an investigational oral, brain‑penetrant BTK degrader that causes cells to remove the BTK protein rather than only blocking its enzyme activity.
- The plan calls for a Phase 3 start in second‑line chronic lymphocytic leukemia in summer 2026 and Phase 2 trials in multiple sclerosis and chronic spontaneous urticaria to test immunology and neurology uses.
- The transaction must clear customary closing conditions including the Hart‑Scott‑Rodino antitrust waiting period and is expected to close in the third quarter of 2026, with Roche citing a large NHL/CLL market opportunity that could affect future pricing and access.